title: Presence of HIV-1 neutralizing IgA antibodies in primary HIV-1 infected patients.
abstract: The initial control of viral replication during primary HIV-1 infection is dominated by CD8+ T-cell mediated responses. Neutralizing IgG to autologous virus is first detected in serum weeks after this response when the viraemia has already declined. However, the mucosal and systemic HIV-1 neutralizing IgA response during primary HIV-1 infection in patients treated with HAART has not been studied previously. The presence of HIV-1 neutralizing IgA antibodies in serum (n=10 patients) and semen (n=6 patients) samples was tested against a laboratory adapted HIV-1 isolate and against primary HIV-1 isolates, representing different clades and phenotypes. The patients received HAART during the study period and were followed from primary HIV-1 infection and up to 72 weeks. Overall, HIV-1 neutralizing IgA activity could be demonstrated in serum from 5 of 10 primary HIV-1 infected patients at inclusion, although the response was restricted to only 1 of the 4 tested isolates. In semen samples, HIV-1 neutralizing IgA activity was seen in 2 of 5 patients against at least 1 of the HIV-1 isolates. In conclusion, a restricted but early neutralizing IgA response can be detected in serum and semen in primary infected patients treated with HAART.
authors.affiliation: Division of Clinical Virology, Karolinska Institute, 141 86 Stockholm, Sweden. johan.soderlund@labmed.ki.se
authors.forename: Johan
authors.initials: J
authors.lastname: Söderlund
authors.forename: Taha
authors.initials: T
authors.lastname: Hirbod
authors.forename: Li-Ean
authors.initials: LE
authors.lastname: Goh
authors.forename: Jan
authors.initials: J
authors.lastname: Andersson
authors.forename: Kristina
authors.initials: K
authors.lastname: Broliden
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000097:blood / Q000276:immunology*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D015331:Cohort Studies; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D015497:HIV-1 / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis / Q000276:immunology*; D008297:Male; D011379:Prognosis; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000888:Antibodies, Anti-Idiotypic; D007070:Immunoglobulin A